MedTrace Logo

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

NCT01592240 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2017-12-05

Study results available
· View outcomes & findings →

Summary

To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.

Conditions

Interventions

DRUG

PBO

Placebo Q28d

DRUG

200mg PF-04950615 (RN316)

PF-04950615 200 mg, Q28d

DRUG

300mg PF-04950615 (RN316)

PF-04950615 300 mg, Q28d

DRUG

PBO

Placebo, Q14d

DRUG

PF-04950615

PF-04950615 50mg, Q14d

DRUG

PF-04950615

PF-04950615 100 mg, Q14d

DRUG

PF-04950615

PF-04950615 150mg, Q14d

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-04-30
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592240 on ClinicalTrials.gov